

Time for HOPE? Precision Medicine in Modern Psychiatry and Neurodevelopmental disorders

Modern medicine looks at the psychiatric disorders as heterogeneous conditions arising from the interaction of neurobiology, genetics, environment, and life habits. Epigenetic mechanisms that control global genome functioning are relevant drivers in psychiatric conditions.

With the latest findings in the field, LSD1 has emerged as a molecular hub where several defective pathways converge to produce a disease phenotype. LSD1 inhibition has been shown to rescue complex phenotypes in genetic models of CNS and neurodevelopmental conditions.

These findings open, for first time, the door to consider genetically defined pharmaceutical interventions in certain CNS patient subpopulations.

In this panel, we will address the complexities, challenges and promises of this precision medicine approach in the CNS space

Moderator:

- **Tamara Maes**, Chairman of the Scientific Advisory Board, ORYZON (Spain)

Speakers:

- **Josep Antoni Ramos-Quiroga**. Head of Department of Psychiatry. Department of Psychiatry. CIBERSAM. Hospital Universitari Vall d'Hebron, Barcelona (Spain)
- **Julian Nevado**. Responsable de Genómica Estructural y Funcional. INGEMM (Instituto de Genética Médica y Molecular). Hospital Universitario La Paz, Madrid (Spain)
- **Jaqueline Harris**. Assistant Professor of Neurology, Genetics, and Pediatrics. Kennedy Krieger Institute. Johns Hopkins Medical Institution (USA)
- **Alfredo Martinez**. Director Gerente en Complejo Hospitalario de Navarra. Servicio Navarro de Salud-Osasunbidea Pamplona/Iruña (Spain)